STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study
And other biotech news brought to you by The Readout
STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more
Pharmaceutical companies are boosting their spending on lobbying firms with connections to the White House
Paediatrician booked after 6-month-old allegedly given expired injection dies
Hyderabad: A case of alleged medical negligence has been registered against a paediatrician following the death of a six-month-old infant who was reportedly administered an expired injection at a private…
ICMR hosts SANVAD 2026 to promote high-quality doctoral research
New Delhi: The Indian Council of Medical Research (ICMR), under the Department of Health Research (DHR), Ministry of Health and Family Welfare, organized SANVAD 2026 (Scholars' Assembly for Next-gen Ventures…
NMC proposes mandatory dedicated corpus fund for running medical colleges
New Delhi: The National Medical Commission (NMC) has proposed making it mandatory for medical colleges to maintain a dedicated corpus fund, as part of draft amendments to the Establishment of…
Newborn dies after sweeper attempts delivery at Surguja CHC, family alleges negligence
Surguja: In a shocking incident at Kunni Village Community Health Centre (CHC) in Chhattisgarh's Surguja, a newborn died during delivery after a sweeper reportedly tried to assist the birth in…
STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study
Novo Nordisk's next-generation obesity drug CagriSema underperformed versus Eli Lilly's Zepbound in a head-to-head study.
RD Gardi medical college MBBS student dies after being hit by speeding truck
Ujjain: In a tragic incident, a second-year MBBS student died in a road accident in Ujjain. The incident occurred Saturday morning when he was hit by a speeding truck near…
STAT+: Pharma lobbyists focus on a surprising new target: the FDA
Lobbyists told STAT they believe the odds of approval go up if a decision can be spun as a win for the Trump administration.
STAT+: Lobbying firms with close ties to Trump draw pharma industry clients
Business is booming for Trump-connected lobbying firms as pharma giants see new opportunity to influence the FDA.